Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin
about
Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactionsCombining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical dataUsing semantic predications to uncover drug-drug interactions in clinical data.Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk.Text mining for drug-drug interaction.A novel algorithm for analyzing drug-drug interactions from MEDLINE literature.Evaluating Term Coverage of Herbal and Dietary Supplements in Electronic Health Records.A Semi-Mechanistic Metabolism Model of CYP3A Substrates in Pregnancy: Predicting Changes in Midazolam and Nifedipine Pharmacokinetics.Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycinStereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems.Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies.Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A.Development of a biocompatible creatinine-based niosomal delivery system for enhanced oral bioavailability of clarithromycin.Pharmacological indices and pulmonary distribution of rifampicin after repeated oral administration in healthy foals.Effect of clarithromycin and fluconazole on the pharmacokinetics of montelukast in human volunteers.Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor.A quantitative systems pharmacology approach, incorporating a novel liver model, for predicting pharmacokinetic drug-drug interactions.Mania induced by clarithromycin in a geriatric patient taking low-dose prednisone.Bilateral diffuse iris atrophy after the use of oral clarithromycin.Development of an Adult Physiologically Based Pharmacokinetic Model of Solithromycin in Plasma and Epithelial Lining Fluid.Physiologically based pharmacokinetic modeling of SNU-0039, an anti-Alzheimer's agent, in rats."Drugs on oxygen": an update and perspective on the role of cytochrome P450 testing in pharmacology.Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.
P2860
Q28482155-E9208B7D-944F-40F3-9838-40AD1DD28563Q30666721-B437F169-E813-442F-A5B1-3D791CA75B24Q30739020-0A9AFB85-DA08-45F2-8D21-E7EFE0D99285Q30776360-5735FA17-BA73-476D-9776-16AA96F66709Q36259408-6C8E8418-6DF8-4AB7-AD81-A570C33139D5Q36323871-63459E00-B8D8-4CC6-AE2D-48654ED794BAQ36613287-C5EC700F-EC34-4747-9782-4DEBE16456DCQ36702463-D93BA5F8-2C36-4640-85F4-30D88F980737Q37016344-02E0B0DB-667F-4D86-9FD7-79BB397FD9CBQ37325598-0A161D54-915F-463D-B4E2-2B29741761AAQ38205664-8EA8B091-B5C7-47E8-8FBD-93C427287665Q38420688-B633F51E-4D56-4C85-A7FF-C5A12E5B9937Q38726643-6B39EF94-13D5-4F96-ABEE-2F28DDCC4009Q38767228-AA027BE6-3541-4324-97F4-8163F60E81E5Q38773623-1AD047DE-F14C-4727-BD26-7C835EB90AA1Q39062284-4A75D44B-9E40-46DD-B1F6-5715104FE6D9Q39643626-931A9B8E-CC25-466A-8E34-A0DCE1E23D86Q41072555-74552CEF-60B3-4F43-8099-2AD80B9BFD58Q42072078-9E22DF60-B2DD-4DC8-B648-A4D981CC9D72Q46741874-F971A337-AAD0-46E4-A613-312B035B0416Q47134454-BB71AB91-FA90-4285-ACBF-503FB13AAB7FQ48933554-E00CAFD7-6841-409A-9624-D9C51D008D73Q51557998-36A900FA-213E-4201-B3FD-AFCC8151B416Q52334679-AB2E56C5-52F7-413F-B3E9-84D09A2F749B
P2860
Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Physiologically based pharmaco ...... ion of CYP3A by clarithromycin
@ast
Physiologically based pharmaco ...... ion of CYP3A by clarithromycin
@en
type
label
Physiologically based pharmaco ...... ion of CYP3A by clarithromycin
@ast
Physiologically based pharmaco ...... ion of CYP3A by clarithromycin
@en
prefLabel
Physiologically based pharmaco ...... ion of CYP3A by clarithromycin
@ast
Physiologically based pharmaco ...... ion of CYP3A by clarithromycin
@en
P2093
P2860
P356
P1476
Physiologically based pharmaco ...... ion of CYP3A by clarithromycin
@en
P2093
Aroonrut Lucksiri
J Christopher Gorski
Sara K Quinney
Stephen D Hall
P2860
P304
P356
10.1124/DMD.109.028746
P577
2009-11-02T00:00:00Z